GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (STU:8EM) » Definitions » Short Interest

Editas Medicine (STU:8EM) Short Interest


View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Editas Medicine's Short Interest

For the Biotechnology subindustry, Editas Medicine's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Editas Medicine's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's Short Interest distribution charts can be found below:

* The bar in red indicates where Editas Medicine's Short Interest falls into.


Editas Medicine (STU:8EM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (STU:8EM) » Definitions » Short Interest
Comparable Companies
HLVX OABI TRDA PHAT TVTX ETNB ARCT SVRA WVE ELVN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
EDIT:USA 0IFK:UK 8EM:Germany
Address
11 Hurley Street, Cambridge, MA, USA, 02141
Website
https://www.editasmedicine.com
Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Editas Medicine (STU:8EM) Headlines

No Headlines